Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$12.50
-$0.03(-0.56%)
At close: 4:00 PM EDT
$12.50
-$0.03(-0.56%)
Day’s Range― - ―
52-Week Range$2.75 - $15.02
Previous CloseN/A
Volume984.13K
Average Volume (3M)4.89M
Market Cap
$3.82B
Enterprise Value$1.97B
Total Cash (Recent Filing)$540.10M
Total Debt (Recent Filing)$135.62M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Nov 09, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding324,047,360
10 Day Avg. Volume5,361,823
30 Day Avg. Volume4,887,791
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue29.76
Enterprise Value/Gross Profit39.70
Enterprise Value/Ebitda-11.65
Forecast
1Y Price Target
$16.78Price Target Upside34.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$26.30M
Bulls Say, Bears Say
Bulls Say
Liquidity And RunwaySubstantial liquidity gives AbCellera time to fund clinical development and platform investment without immediate dependence on capital markets. The extended runway can support multiple programs through important milestones, preserving strategic flexibility while partners and internal assets mature.
Strategic PartnershipsLarge pharmaceutical partnerships validate AbCellera’s discovery capabilities while transferring significant development funding and risk to partners. Upfronts, milestones, and royalties create potential revenue leverage if programs advance, strengthening the platform’s long-term commercial model.
Pipeline AdvancementProgress across lead clinical programs creates identifiable value inflection points beyond the partnered-services business. Advancing assets through trials can demonstrate platform productivity, support future partnering economics, and broaden AbCellera’s potential sources of long-term revenue.
Bears Say
Persistent Operating LossesThe current revenue base does not yet support AbCellera’s cost structure, producing large operating and net losses. Sustained losses can consume equity and require continued funding, while the sharp reversal from earlier profitability highlights elevated earnings volatility and execution risk.
Revenue Volatility And DependenceLow and irregular revenue makes financial performance dependent on the timing of research activity, upfronts, and milestones rather than a stable recurring base. That variability complicates planning and leaves results exposed to partner decisions and the uneven progression of programs.
Clinical And Execution UncertaintyClinical uncertainty around ABCL635 could delay validation of the internal pipeline, particularly where placebo effects may obscure efficacy. The missed IND-enabling timeline also indicates execution can lag internal plans, potentially postponing future catalysts and partnering opportunities.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $2.75 and its highest was $15.02 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $3.82B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Nov 09, 2026 which is in 21 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Aug 05, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.016.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.18.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 324,047,360 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went up 10.304%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.78 (34.22% Upside)
$16.78 (34.22% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 84%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.6%
Last 30 Days <0.1%
Last 30 Days <0.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.05%
12-Months-Change
Fundamentals
Return on Equity
-17.49%
Trailing 12-Months
Asset Growth
-6.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbCellera Biologics
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$16.78
▲(34.22% Upside)
Technical Analysis
Ownership Overview
38.60% Insiders
4.40% Mutual Funds
0.01% Other Institutional Investors
55.48% Public Companies and Individual Investors